About Us

We are a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by gastroenterologists and other physicians. Key elements of our business strategy include:

Increasing sales of our ZEGERID^® and GLUMETZA^® brand prescription products
- ZEGERID (omeprazole/sodium bicarbonate) Capsules and Powder for Oral Suspension for the treatment of certain upper gastrointestinal diseases and disorders (for full prescribing and safety information visit www.zegerid.com), and
- GLUMETZA (metformin hydrochloride extended release tablets), which is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (for full prescribing and safety information visit www.glumetzaxr.com).
Advancing the development of budesonide MMX^® and rifamycin SV MMX^®, our two lower gastrointestinal product candidates
- Budesonide MMX is being investigated in two multicenter Phase III clinical trials for the induction of remission of mild or moderate ulcerative colitis.
- Rifamycin SV MMX has been investigated in a Phase II clinical program in travelers' diarrhea.
Maximizing the value of our proprietary proton pump inhibitor (PPI) technology through strategic alliances
Expanding our product portfolio to further leverage our commercial capabilities

Our goal is to become a premier specialty biopharmaceutical company with a diversified portfolio of commercial and development products. Our stock trades on the NASDAQ Global Market under the symbol "SNTS".